Skip to main content
SpringerLink
Log in

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Melanoma chondroitin sulfate proteoglycan (MCSP; also called CSPG4, NG2, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a surface antigen frequently expressed on human melanoma cells, which is involved in cell adhesion, invasion and spreading, angiogenesis, complement inhibition, and signaling. MCSP has therefore been frequently selected as target antigen for development of antibody- and vaccine-based therapeutic approaches. We have here used a large panel of monoclonal antibodies against human MCSP for generation of single-chain MCSP/CD3-bispecific antibodies of the BiTE (for bispecific T cell engager) class. Despite similar binding affinity to MCSP, respective BiTE antibodies greatly differed in their potency of redirected lysis of CHO cells stably transfected with full-length human MCSP, or with various MCSP deletion mutants and fusion proteins. BiTE antibodies binding to the membrane proximal domain D3 of MCSP were more potent than those binding to more distal domains. This epitope distance effect was corroborated with EpCAM/CD3-bispecific BiTE antibody MT110 by testing various fusion proteins between MCSP and EpCAM as surface antigens. CHO cells expressing small surface target antigens were generally better lysed than those expressing larger target antigens, indicating that antigen size was also an important determinant for the potency of BiTE antibody. The present study for the first time relates the positioning of binding domains and size of surface antigens to the potency of target cell lysis by BiTE-redirected cytotoxic T cells. In case of the MCSP antigen, this provides the basis for selection of a maximally potent BiTE antibody candidate for development of a novel melanoma therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200–205

    Article  CAS  PubMed  Google Scholar 

  2. King J, Waxman J, Stauss H (2008) Advances in tumour immunotherapy. QJM 101:675–683

    Article  CAS  PubMed  Google Scholar 

  3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predicts clinical outcome. Science 313:1960–1964

    Article  CAS  PubMed  Google Scholar 

  4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213

    Article  CAS  PubMed  Google Scholar 

  5. Wahlin BE, Sander B, Christensson B, Kimby E (2007) CD8 + T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 13:388–397

    Article  CAS  PubMed  Google Scholar 

  6. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S (2007) In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 204:345–356

    Article  CAS  PubMed  Google Scholar 

  7. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106:3360–3365

    Article  CAS  PubMed  Google Scholar 

  8. Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A (2009) Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM × Anti-CD3): results of a phase 1/2 study. J Immunother 32:195–202

    Article  CAS  PubMed  Google Scholar 

  9. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23:8968–8977

    Article  CAS  PubMed  Google Scholar 

  10. Langer LF, Clay TM, Morse MA (2007) Update on CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7:1245–1256

    Article  CAS  PubMed  Google Scholar 

  11. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854

    Article  CAS  PubMed  Google Scholar 

  12. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28:53–62

    Article  PubMed  Google Scholar 

  13. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308

    Article  CAS  PubMed  Google Scholar 

  14. Harzstark AL, Small EJ (2007) Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther 7:1275–1280

    Article  CAS  PubMed  Google Scholar 

  15. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296

    Article  CAS  PubMed  Google Scholar 

  16. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974–977

    Article  CAS  PubMed  Google Scholar 

  17. Topp M, Goekbuget N, Kufer P et al (2008) Treatment with anti-CD19 BiTE antibody blinatumomab (MT103/MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lmphoblastic leukemia (ALL): first results of ongoing phase 2 study (ASH Annual Meeting Abstract). Blood 112:1926

    Google Scholar 

  18. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69:4941–4944

    Article  CAS  PubMed  Google Scholar 

  19. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43:1129–1143

    Article  CAS  PubMed  Google Scholar 

  20. Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P (2009) Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 32:341–352

    Article  CAS  PubMed  Google Scholar 

  21. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA (2007) Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res 67:3927–3935

    Article  CAS  PubMed  Google Scholar 

  22. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 115:98–104

    Article  CAS  PubMed  Google Scholar 

  23. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuese R, Schlereth B, Kufer P, Baeuerle PA (2009) Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214:441–453

    Article  CAS  PubMed  Google Scholar 

  24. Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB (1991) The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 114:359–371

    Article  CAS  PubMed  Google Scholar 

  25. Burg MA, Grako KA, Stallcup WB (1998) Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 177:299–312

    Article  CAS  PubMed  Google Scholar 

  26. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J (1999) Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1:507–513

    Article  CAS  PubMed  Google Scholar 

  27. Fang X, Burg MA, Barritt D, Dahlin-Huppe K, Nishiyama A, Stallcup WB (1999) Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol Biol Cell 10:3373–3387

    CAS  PubMed  Google Scholar 

  28. Natali PG, Bigotti A, Cavaliere R, Nicotra MR, Ferrone S (1984) Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst 73:13–24

    CAS  PubMed  Google Scholar 

  29. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H (2005) Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 114:426–432

    Article  CAS  PubMed  Google Scholar 

  30. Ruf P, Jäger M, Ellwart J, Wosch S, Kusterer E, Lindhofer H (2004) Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 108:725–732

    Article  CAS  PubMed  Google Scholar 

  31. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466–470

    Article  CAS  PubMed  Google Scholar 

  32. Spitler LE, del Rio M, Khentigan A et al (1987) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47:1717–1723

    CAS  PubMed  Google Scholar 

  33. Pfosser A, Brandl M, Salih H, Grosse-Hovest L, Jung G (1999) Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int J Cancer 80:612–616

    Article  CAS  PubMed  Google Scholar 

  34. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710–9715

    Article  CAS  PubMed  Google Scholar 

  35. Raum T, Gruber R, Riethmüller G, Kufer P (2001) Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 50:141–150

    Article  CAS  PubMed  Google Scholar 

  36. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, Schlereth B, Baeuerle PA (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 30:798–807

    Article  CAS  PubMed  Google Scholar 

  37. Tillet E, Ruggiero F, Nishiyama A, Stallcup WB (1997) The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J Biol Chem 272:10769–10776

    Article  CAS  PubMed  Google Scholar 

  38. Stinchcombe JC, Bossi G, Booth S, Griffiths GM (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15:751–761

    Article  CAS  PubMed  Google Scholar 

  39. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43:763–771

    Article  CAS  PubMed  Google Scholar 

  40. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV (1999) The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 246:108–121

    Article  CAS  PubMed  Google Scholar 

  41. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134–141

    Article  CAS  PubMed  Google Scholar 

  42. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA (1998) Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279:1166–1172

    Article  CAS  PubMed  Google Scholar 

  43. Sun ZJ, Kim KS, Wagner G, Reinherz EL (2001) Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer. Cell 105:913–923

    Article  CAS  PubMed  Google Scholar 

  44. Torisu-Itakura H, Schoellhammer H, Huynh Y, Hausmann S, Lutterbuese R, Kufer P, Baeuerle PA, Morton DL (2009) Anti-tumor activity of a T cell-engaging MCSP-specific BiTE antibody at very low effector to target ratios: a new approach to treat metastatic melanoma. Am Assoc Cancer Res Abstract 3248

Download references

Author information

Authors and Affiliations

  1. Micromet AG, Staffelseestr. 2, 81477, Munich, Germany

    Claudia Bluemel, Susanne Hausmann, Petra Fluhr, Mirnalini Sriskandarajah, Patrick A. Baeuerle & Peter Kufer

  2. Micromet, Inc., 6707 Democracy Blvd., Bethesda, MD, 20217, USA

    Patrick A. Baeuerle

  3. Sanford-Burnham Institute for Medical Research, Cancer Research Center, La Jolla, CA, 92037, USA

    William B. Stallcup

Authors
  1. Claudia Bluemel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Hausmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petra Fluhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mirnalini Sriskandarajah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William B. Stallcup
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patrick A. Baeuerle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Kufer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick A. Baeuerle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bluemel, C., Hausmann, S., Fluhr, P. et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 59, 1197–1209 (2010). https://doi.org/10.1007/s00262-010-0844-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-010-0844-y

Keywords

Search

Navigation